The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited
Abstract
OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Self-citation
Cited by
Items 401–500 of 555
Werner, C., Muller, N., & Müller, U. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01296-8 · Cited by 3
Current Status of Islet Transplantation
Cravedi, P., Ruggenenti, P. L., Remuzzi, A., & Remuzzi, G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398523-1.00040-9 · Cited by 3
Technophobia, prescription checking and the future of diabetes management
Albisser, A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1341-8 · Cited by 3
“Notably, HbA1c has been determined to explain virtually all of the difference in the risk of complications between the intensive and conventional groups [4].”
BackgroundLachin, J. M., Nathan, D. M., Zinman, B., & Bebu, I. (2020) · Diabetes · doi:10.2337/db20-0311 · Cited by 3
“” The association of A1c months, a measure of glycemic exposure, with complications is expected based on the strong association of complications with mean HbA1c in DCCT/EDIC (3).”
BackgroundInfluentialSelf-citationOliveira, S., Guimarães, P., Roque-Rosado, Â., Campos, E. J., Serranho, P., Matafome, P. N., Bernardes, R. C., & Ambrósio, A. F. (2025) · Eye and Vision · doi:10.1186/s40662-025-00451-3 · Cited by 4
“Given the strong correlation between HbA1c levels and DR [43], another limitation of this study arises from the low HbA1c levels detected in animals treated with HFD and STZ.”
Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients
Roth, L., Stein, J., & Schwarz, P. E. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6671361 · Cited by 2
Mankad, R. N., Marek, L., Acosta, G., Cabrera, A. P., Monickaraj, F., Qualls, C., & DAS, A. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7203748 · Cited by 2
“A post hoc analysis of the DCCT showed that total glycemic exposure, including HbA1c, may only account for 11% of the risk of developing PDR [16].”
Hamilton, P., McCann, A. J., Agnew, C. E., Millar, A., McClenaghan, V., McGivern, R. C., & McVeigh, G. E. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411435748 · Cited by 2
Bıçaklıoğlu, F., Koparal, M. Y., Bulut, E. C., Barlas, İ. Ş., Küpeli, B., & Şen, İ. (2019) · Journal of Urological Surgery · doi:10.4274/jus.galenos.2019.2500 · Cited by 2
Forga, L., López‐Andrés, N., Tamayo, I., Fernández‐Celis, A., Mouriz, M. G., & Goñi, M. J. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.007 · Cited by 2
Jun, J. E., Lee, Y., & Kim, J. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241288579 · Cited by 2
Chen, J., Li, Y., Niu, Z., He, Z., Xie, Y. J., Hernández, J., Huang, W., Wang, H., & on Behalf of the Guangzhou Diabetic Eye Study Group (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0239 · Cited by 4
“Previous studies have indicated the possibility of biological mechanisms independent of known risk factors that may serve as additional determinants of the risk of DR progression over time, which require further investigation [15,46].”
Balderas-Martínez, Y. I., Sánchez-Rojas, J. A., Téllez‐Velázquez, A., Martínez, F. J., Cruz‐Barbosa, R., Guzmán‐Ramírez, E., García, I., & Arroyo‐Fernández, I. (2025) · Big Data and Cognitive Computing · doi:10.3390/bdcc9060162 · Cited by 3
Multi-omics profiling reveals liver–retina axis in high-fat diet-induced early retinopathy
Zhang, X., Xia, M., Liu, Y., Yang, M., Zhang, X., Chen, F., Wang, X., Feng, Z., Wu, Y., & Zhang, F. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152516 · Cited by 2
HbA1c pour le diagnostic et le suivi du diabète: Le point de vue du diabétologue
Larger, É., Lemoine, A. Y., Gonfroy‐Leymarie, C., & Borie‐Swinburne, C. (2012) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(12)71326-6 · Cited by 2
Dreyer, M. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0112-7 · Cited by 2
Priyadharshini, N., Annamalai, R., & Muthukumar, M. (2017) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2017.i01.09 · Cited by 2
Genetics of diabetic retinopathy
Isildak, H., Schwartz, S. G., & Brantley, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00012-5 · Cited by 2
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50004-9 · Cited by 2
Glycemic Index and Diabetes Mellitus
(2016) · CRC Press eBooks · doi:10.1201/9781315371764-5 · Cited by 2
Lind, M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 10
Diabetes Mellitus Associated Progressive Neurovascular Retinal Injury
Sinclair, S. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-25779-7_18 · Cited by 1
Sacchetta, L., Tricò, D., & Solini, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00011-7 · Cited by 1
Yakob, T., Abraham, A., Yakob, B., & Jaldo, M. M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1462210 · Cited by 4
“According to the study, hyperglycemia only accounts for 11% of the overall risk of DR; the remaining 89% may be attributable to other possible risk factors (31).”
The Danish ophthalmological society guidelines for treatment of diabetic retinopathy
Grauslund, J., Bloch, S. B., Hajari, J. N., Laugesen, C. S., Lind, M., Nielsen, M. S., Schielke, K. C., & Subhi, Y. (2025) · AJO International · doi:10.1016/j.ajoint.2025.100146 · Cited by 1
Report of the 2023 Mary Tyler Moore Vision Initiative Workshop
Levine, S. R., Markel, D. S., Myers, M. G., Barunas, R., Sun, J. K., Chang, D. S.-T., Maguire, M. G., Vujosevic, S., Fort, P. E., Atkinson, M. A., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.7.11 · Cited by 1
“13 The DCCT also showed there is familial clustering in development of severe NPDR and PDR.”
Analysis of 24 pro-inflammatory cytokines in aqueous and serum of 94 patients without diabetes
Kim, S. J., Gangaputra, S. S., Sheng, J., Patel, S. N., Nair, A. A., Awamlh, S. A. H. A., Fitzpatrick, J., Cherney, E. F., Veach, L., & Nicholson, C. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-327421 · Cited by 1
Taherian, M. R., Etemad, K., Sadeghi, S., Jorjani, G., & Nazari, S. S. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/8029111 · Cited by 1
Ma, J., Qin, J., Mao, F., Chang-lin, H., Ma, D., & Zhu, J. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05326-y · Cited by 3
“Indeed, even patients with the same HbA1c levels may experience markedly different complication rate [22, 36, 37].”
Durmaz, D., & Özen, M. (2025) · Pamukkale Medical Journal · doi:10.31362/patd.1721919 · Cited by 1
Magaña‐Guerrero, F. S., Buentello‐Volante, B., Magaña-Guerrero, N. A., Vivanco-Rojas, Ó., Domínguez-López, A., & Garfias, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021102 · Cited by 1
“Chronic hyperglycemia also promotes the formation of reactive carbonyl species such as methylglyoxal, which drives advanced glycation end-product (AGE) formation and protein dysfunction, contributing to insulin resistance, vascular damage, and diabetic complication [3].”
Liu, J., Jiang, W., Liang, J., Ye, X., Yang, X., Wang, Q., Chen, M., Meng, H., Shen, Q., Zhong, Y., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1674977 · Cited by 1
“…as a protective factor and TSH as a secondary risk factor, while FT4 showed no signi fi cant association with DKD. Studies have shown that among diabetic patients with similar HbA1c levels, those with greater fl uctuations in blood glucose have a higher risk of developing chronic complications (29).”
Bian, L., Yang, C., Jin, Y., Wang, H., Zhu, M., Xu, J., Bai, J., Zhang, M., Liu, Y., Yang, T., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341915 · Cited by 2
Inflammatory Biomarkers in Diabetic Macular Edema
Campos, A., Furtado, M. J., Carneiro, Â., Meireles, A., Marques‐Neves, C., Ambrósio, A. F., Leal, I., Figueira, J., Marques, J. P., Henriques, J., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051949 · Cited by 1
Ferroptosis in diabetic retinopathy: cellular heterogeneity, progression, and therapeutic targets
Liu, C., Zhu, L., Gao, F., Jin, C., Tian, H., Xu, G.-T., Zhang, L., & Lü, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11692-3 · Cited by 1
Barba-Gallardo, L. F., Ávila‐Blanco, M. E., Ventura‐Juárez, J., Muñoz‐Ortega, M. H., Murillo-Ruíz, R. C., Rivera-Delgadillo, M., Díaz-Rubio, J. L., Casillas-Casillas, E., Salas-Hernández, L. H., & Guerra-Ávila, P. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083427 · Cited by 1
Reaven, P. D., Macwan, S. A., McConeghy, K. W., Norman, G. J., Conlin, P. R., Miller, D. R., & Zhou, J. J. (2026) · Diabetes Care · doi:10.2337/dc26-0425 · Cited by 1
Sawyer, A., Towers, L., LANGE, S., Buros‐Stein, A., Berget, C., & Forlenza, G. P. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261467128 · Cited by 2
HbA1c reconsidered: glycated haemoglobin in the era of dynamic erythrocyte glucose metabolism
Hsieh, M.-Y. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02800-7 · Cited by 1
Rodriguez, S. M., Hamill, E. B., Sundaresan, A., Guffey, D., & Weng, C. Y. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000544 · Cited by 1
“36 It may be that many systemic variables affect an individual ’ s susceptibility to diabetic micro-vascular complications, or it may be the case that underlying genetic factors play a larger role than previously established.”
Gerdes, C., Werner, C., Kloos, C., Lehmann, T., Wolf, G., Müller, U., & Muller, N. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1192-3761 · Cited by 2
Understanding Glycemic Variability: Focus on Diabetic Kidney Disease
Purandare, V. B., Bale, C., Kakrani, A. L., & Unnikrishnan, A. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_3_21 · Cited by 1
Diabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0217 · Cited by 1
Knowledge of Students in Health and Non-Health Studies about Diabetes Mellitus Type 1
Kolačko, Š., Kokot, A., Čuljak, N., Predović, J., Hrvačić, M., Luetić, F., & Bašković, M. (2024) · Southeastern European medical journal · doi:10.26332/seemedj.v7i2.290 · Cited by 1
Roth, L., Wagner, C., Riesner, P., Krage, B., Steckhan, N., & Schwarz, P. E. H. (2025) · Diabetology · doi:10.3390/diabetology6090085 · Cited by 2
V-Go Insulin Delivery Device: A New Tool for Primary Care Settings
Krichten, C. M., Kapustin, J. F., Ghabranious, M., & Mewborn, A. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.09.005 · Cited by 1
¿Qué podemos esperar del control de la variabilidad glucémica?
Gómez, M. D. (2014) · Avances en Diabetología · doi:10.1016/j.avdiab.2014.03.001 · Cited by 3
Cryer, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00034-4 · Cited by 5
Patient Education As an Independent Treatment Factor of Type 2 Diabetes Management
Матюха, Л. Ф., & Смаль, Б. О. (2019) · Family Medicine · doi:10.30841/2307-5112.3.2019.178573 · Cited by 2
Suh, S., & Kim, J. H. (2014) · Journal of Korean Diabetes · doi:10.4093/jkd.2014.15.4.196 · Cited by 2
Diabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1515-9155 · Cited by 1
Diabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2022) · Der Diabetologe · doi:10.1007/s11428-022-00882-9 · Cited by 1
Sämann, A., & Wolf, G. (2013) · Der Nephrologe · doi:10.1007/s11560-013-0779-3 · Cited by 1
“Schwere Hypoglykämien, Gewichtszunahme sowie Kombinationen von oralen Antidiabetika und Insulin stehen im Verdacht, die Mortalität sowie Morbidität von Patienten mit Typ-2-Diabetes zu er- Als besonders vorteilhaft hat sich eine antidiabetische, antihypertensive und lipidmodifizierende Langzeittherapie erwiesen Entsche…”
InfluentialMoreno-Fernández, J., García-Seco, J. A., Virlaboa-Cebrian, R., Seco, A. M., Muñoz‐Rodríguez, J. R., & Romero, F. J. G. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.12.012 · Cited by 1
Die Verordnung einer Insulinpumpe aus Sicht des MDK
Habrich, G. (2009) · Der Diabetologe · doi:10.1007/s11428-008-0381-x · Cited by 1
Role of IGF‐1 and glycaemic control in diabetic retinopathy
Triebel, J. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02654.x · Cited by 1
Jönsson, L. (2014) · Lund University Publications (Lund University) · Cited by 1
Roth, L., Wagner, C., Riesner, P., Krage, B., Steckhan, N., & Schwarz, P. E. H. (2024) · doi:10.2196/preprints.68721 · Cited by 1
Diabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01271-0 · Cited by 1
Savadatti, S. S. (2015) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/3wwp-hzsp · Cited by 1
Haptoglobin Genotype and Diabetic Retinopathy
Goldenberg‐Cohen, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-401717-7.00055-1 · Cited by 1
Education for Teenagers with Type 1 Diabetes
Viklund, G. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
Begg, I. S., Warnock, G. L., & Thompson, D. M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-150-9_20 · Cited by 1
Continuous monitoring blood glucose level in clinical practice and new methods for its analysis
Dreval', A. V., Dreval, O., & Starostina, E. G. (2013) · Problems of Endocrinology · doi:10.14341/probl201359441-49 · Cited by 3
Almokayyad, R. M., & Cuddihy, R. M. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch7
The Epidemiology of Macrovascular Complications of Diabetes in Finland 1992-2002
Winell, K. (2013) · Työväentutkimus Vuosikirja · Cited by 2
Early autonomic dysfunction in type 1 diabetes : Insights into its significance and mechanisms
Rosengård‐Bärlund, M. (2014) · Työväentutkimus Vuosikirja
El-Samahy, M. H., Adly, A. A., El-Gindi, H. D., & El-Ghaffar, H. H. (2009)
Detection and Treatment of Type 1 Diabetes
Mazze, R. S., APRN-BC, F. E. S. S., Bergenstal, R. M., Criego, A. B., Cuddihy, R. M., Langer, O., Simonson, G. D., & Powers, M. A. (2011) · Wiley eBooks · doi:10.1002/9781119950424.ch4
Clinical studies of glucose variability and hypoglycemia in adult patients with type 1 diabetes
Bragd, J. (2011) · Figshare · Cited by 2
Insulintherapie bei Diabetes Typ 1
Dreyer, M. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1150-z
Padma, V., & Sugumar, V. R. (2014) · FoodSci Indian Journal of Research in Food Science and Nutrition · doi:10.15613/fijrfn/2014/v1i1/53843
Role of Glucose Derived Reactive Metabolites in Diabetic Nephropathy
Parchwani, D. N., Patel, D., & Patel, D. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-015-0486-0
“although poor glycemic control is clearly a risk factor [2], accelerated DN may occur in some individuals with good glycemic control, whereas others whose glycemic control may be inadequate remain relatively free of complication for many years [7].”
BackgroundFreeman, J. S. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2012.10.004
Tomić, J. (2013) · University Library - University of Saskatchewan (University of Saskatchewan)
Variabilité glycémique et hyperglycémie postprandiale : quelle importance au-delà del’HbA1c?
Monnier, L., Colette, C., Wojtusciszyn, A., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30260-1
Cunha-Vaz, J. G., Ribeiro, L., Nunes, S. G., & Lobo, C. L. (2014)
Abourazzak, S., Dorchy, H., Willems, D., & Mélot, C. (2010)
Tygerberg Hospital in South Africa; A model for diabetes care in sub-Saharan Africa
Urdal, C. (2013) · NORA - Norwegian Open Research Archives
ABOHASSAN, A., Al-Barshomy, S., & Al-kobaty, S. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/729 · Cited by 2
Koo, B. K. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.6.444
Shestakova, M. V., Efremova, N. V., Bolotskaya, L. L., Sklyanik, I. A., Philippov, Y. I., & Dedov, I. I. (2016) · Diabetes Mellitus · doi:10.14341/dm8050
A memória hiperglicêmica no rim diabético: marcas metabólicas, moleculares e epigenéticas
de Oliveira, A. A. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-16032017-162931 · Cited by 1
Larger, É. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30102-5
Complications With Insulin Pump Therapy vs Insulin Injection Therapy
Shah, V. N. (2018) · JAMA · doi:10.1001/jama.2017.20345
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Oikonomou, D. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_9
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00009-3
Glycemic Metrics and Targets in Kidney Disease
Neumiller, J. J., & Hirsch, I. B. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_4
Diabetische Retinopathie bei Patienten mit Diabetes mellitus
Simó‐Servat, O., Hernández, C., & Simó, R. (2019) · Kompass Ophthalmologie · doi:10.1159/000503121
Expression profiles of circRNAs, lncRNAs, and mRNAs in extreme phenotypes of diabetic retinopathyPreprint
Zhou, R., Liu, S., Wang, W., Cheng, W., He, M., Xiong, K., Gong, X., Li, Y., & Huang, W. (2020) · medRxiv · doi:10.1101/2020.02.15.20023481
“Duration of diabetes, hemoglobin A1c, cholesterol and blood pressure only accounted for approximately 10% of the risk of developing retinopathy[6, 7].”
Background(2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00004-4
Uduku, C. N., Reddy, M., & Oliver, N. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00007-7
Diabetes Control, Long-Term Complications, and Large Vessel Disease
Nathan, D. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00051-4
Self-citationWang, W., Zheng, Y., Liu, S., Li, Y., Huang, W., Liang, X., & Liu, Y. (2020) · medRxiv · doi:10.1101/2020.11.22.20236141
“The inclusion criteria of normal controls are: (1) have no history of systemic diseases or operations; (2) have no history of ocular diseases or operations; (3) have normal results of blood tests; (4) have normal results of ocular examination in both anterior and posterior segments; (5) axial length (AL) is less than…”
BackgroundZelinska, P. B. N. B. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-3-26
New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control
Souza, K. L. V. D., Rassi, M. M. B., de Sá, D. A. R., Bussuan, R. M., Rodrigues, L. C. D. S., & Arbex, A. K. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.1.491 · Cited by 1
Metadata
- Authors
- Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Case Western Reserve University (US)
- Harvard University (US)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 995-1001
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1992103610
- Cited by
- 555
- References
- 13
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Clinical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.